ArticleBMC pregnancy and childbirth2026
A nomogram integrating dynamic total bile acid monitoring, medication history, and curative effect for preterm birth prediction in twin pregnancies with intrahepatic cholestasis of pregnancy.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntrahepatic cholestasis of pregnancy (ICP) complicated by twin pregnancy significantly increases the risk of preterm birth, and no tailored predictive tools for gestational age (GA) at delivery have been developed for this specific population to date. This study aimed to develop and validate a twin-specific nomogram with dynamic total bile acid (TBA) monitoring, medication history and curative effect for preterm birth prediction in this population.
methodsA retrospective cohort of 258 twin pregnancies complicated by ICP was enrolled (November 2024-November 2025). The data included demographic, clinical, biochemical (dynamic TBA parameters, liver enzymes), and therapeutic variables (ursodeoxycholic acid (UDCA) usage, combination regimens, TBA response posttreatment). LASSO regression was used to select predictors, which were incorporated into a logistic regression-based nomogram. The model was validated using discrimination (the area under the receiver operating characteristic curve (AUC)), classification accuracy (sensitivity, specificity, PPV, NPV), calibration (Hosmer-Lemeshow test, calibration curves), and clinical utility (decision curve analysis (DCA)).
resultsIn this cohort, the incidence of preterm birth was 83.3%. The independent predictors of preterm birth included GA at ICP diagnosis, UDCA usage, GA at TBA peak, TBA severity group at peak, predelivery TBA (TBA end), aspartate aminotransferase (AST), and treatment curative effect (all P < 0.05). The discriminatory performance of the nomogram, as measured by the area under the curve (AUC), was 0.812 (95% CI: 0.721-0.903) in the training set and 0.740 (95% CI: 0.590-0.889) in the test set. Calibration curves and Hosmer-Lemeshow tests (training set P = 0.1527; test set P = 0.6991) confirmed good agreement between the predicted and actual outcomes. DCA demonstrated significant net benefits across a clinically relevant risk threshold (0-0.833). The model exhibited high specificity (93.8%) and negative predictive value (85.7%) in the test set.
conclusionTo our knowledge, this is among the first nomograms for preterm birth prediction in twin pregnancies with ICP that integrate dynamic TBA monitoring and therapeutic variables. This model is intended primarily as a low-risk exclusion tool to support clinical monitoring strategies, rather than to guide high-risk prediction or delivery decisions. Notably, the model predicts a composite preterm birth outcome modified by both biological risk and clinical intervention rather than purely spontaneous preterm birth, and its low sensitivity further restricts its utility for high-risk preterm birth prediction. Its clinical utility for this purpose requires further rigorous prospective and future external validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.